Table 6.
Risk factors for withdrawal hepatitis by univariable and multivariable analysesa
| Risk factor for WH | Univariable analysis |
Multivariable analysis |
||
|---|---|---|---|---|
| Unadjusted HR (95% CI) | P value | Adjusted HR (95% CI) | P value | |
| Gender | ||||
| Female | 1.00 | |||
| Male | 1.46 (0.53–4.02) | 0.468 | ||
| Age, yr | ||||
| <50 | 1.00 | |||
| ≥50 | 1.53 (0.49–4.80) | 0.470 | ||
| HBeAg | ||||
| Negative | 1.00 | |||
| Positive | 1.12 (1.15–8.58) | 0.916 | ||
| HBV DNA titer, IU/ml | ||||
| <2,000 | 1.00 | 1.00 | ||
| ≥2,000 | 5.55 (1.85–16.7) | 0.002 | 5.90 (1.64–21.3) | 0.007 |
| Liver cirrhosis | ||||
| No | 1.00 | 1.00 | ||
| Yes | 9.68 (3.37–27.8) | <0.0001 | 10.4 (2.38–44.9) | 0.002 |
| Type of malignancy | ||||
| Oncologic | 1.00 | |||
| Hematologic | 2.73 (0.97–7.68) | 0.057 | ||
| Use of steroid | ||||
| No | 1.00 | |||
| Yes | 0.59 (0.21–1.65) | 0.313 | ||
| Use of anthracycline | ||||
| No | 1.00 | |||
| Yes | 1.34 (0.49–3.70) | 0.571 | ||
| Use of rituximab | ||||
| No | 1.00 | |||
| Yes | 3.02 (0.96–9.48) | 0.059 | ||
| Distant metastasis | ||||
| No | 1.00 | 1.00 | ||
| Yes | 2.81 (0.98–8.03) | 0.054 | 5.14 (1.54–17.2) | 0.008 |
a
CI, confidence interval; HR, hazard ratio; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; WH, withdrawal hepatitis. Note that since none of the patients with primary liver cancer showed withdrawal hepatitis, the hazard ratio of primary liver cancer for withdrawal hepatitis could not be estimated.